Sign inJoin waitlistJoin the waitlist

Shailender Bhatia

Director, Melanoma and Renal Cancer Team, Fred Hutch · University of Washington School of Medicine

Credentials: · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Washington-Seattle Campus
2003–2006
Internal Medicine
Univ of Connecticut Health Center/John Dempsey Hospital
2000–2003
ALL INDIA INST OF MED SCI, ANSARI NAGAR, NEW DELHI, DELHI
1996–2000

Research

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
New England Journal of Medicine · 2012 · 6,533 citations
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Cell · 2017 · 1,867 citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
New England Journal of Medicine · 2017 · 1,823 citations

Paul Nghiem
58 papers · 3 as a fellow
JT
John Thompson
31 papers
UP
Upendra Parvathaneni
21 papers
Evan Hall
18 papers
KP
Kelly Paulson
15 papers · 9 as a resident
Song Park
15 papers
JI
Jayasri Iyer
14 papers · 9 as a resident
Sunandana Chandra
11 papers
Tomoko Akaike
11 papers · 2 as a fellow
Jay Liao
10 papers
Sunil Reddy
10 papers
Aude Chapuis
9 papers

Clinical trials

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Principal investigator · Active not recruiting · Phase 2
University of Washington
2023–2027
Adjuvant Avelumab in Merkel Cell Cancer
Principal investigator · Active not recruiting · Phase 3
University of Washington
2017–2029
IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Principal investigator · Completed · Phase 2
OncoSec Medical Incorporated
2012–2015
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Site PI · Recruiting · Phase 2, Phase 3
TuHURA Biosciences, Inc.
2025–2032